[go: up one dir, main page]

LT3246016T - Sausų miltelių vaisto forma, apimanti fosfodiesterazės inhibitorių - Google Patents

Sausų miltelių vaisto forma, apimanti fosfodiesterazės inhibitorių

Info

Publication number
LT3246016T
LT3246016T LTEP17176635.5T LT17176635T LT3246016T LT 3246016 T LT3246016 T LT 3246016T LT 17176635 T LT17176635 T LT 17176635T LT 3246016 T LT3246016 T LT 3246016T
Authority
LT
Lithuania
Prior art keywords
dry powder
form containing
pharmaceutical form
phosphodiesterase inhibitors
powder pharmaceutical
Prior art date
Application number
LTEP17176635.5T
Other languages
English (en)
Inventor
Daniela Cocconi
Francesca Schiaretti
Roberto Bilzi
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of LT3246016T publication Critical patent/LT3246016T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP17176635.5T 2010-08-03 2011-07-27 Sausų miltelių vaisto forma, apimanti fosfodiesterazės inhibitorių LT3246016T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03

Publications (1)

Publication Number Publication Date
LT3246016T true LT3246016T (lt) 2025-05-26

Family

ID=43262631

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17176635.5T LT3246016T (lt) 2010-08-03 2011-07-27 Sausų miltelių vaisto forma, apimanti fosfodiesterazės inhibitorių
LTEP11741172.8T LT2600830T (lt) 2010-08-03 2011-07-27 Sausų miltelių kompozicija, apimanti fosfodiesterazės inhibitorių

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP11741172.8T LT2600830T (lt) 2010-08-03 2011-07-27 Sausų miltelių kompozicija, apimanti fosfodiesterazės inhibitorių

Country Status (39)

Country Link
US (2) US9132121B2 (lt)
EP (2) EP3246016B1 (lt)
JP (1) JP6004233B2 (lt)
KR (1) KR101805958B1 (lt)
CN (2) CN103052379A (lt)
AR (1) AR082443A1 (lt)
AU (1) AU2011287711B2 (lt)
BR (1) BR112013002506A2 (lt)
CA (1) CA2807256C (lt)
CL (1) CL2013000293A1 (lt)
CO (1) CO6690744A2 (lt)
CY (1) CY1120605T1 (lt)
DK (2) DK2600830T3 (lt)
EA (2) EA027692B1 (lt)
ES (2) ES3033142T3 (lt)
FI (1) FI3246016T3 (lt)
GE (1) GEP20156343B (lt)
HR (2) HRP20250711T1 (lt)
HU (2) HUE037620T2 (lt)
IL (1) IL224517B (lt)
LT (2) LT3246016T (lt)
MA (1) MA34449B1 (lt)
ME (1) ME03022B (lt)
MX (1) MX346424B (lt)
MY (1) MY179703A (lt)
NO (1) NO2600830T3 (lt)
NZ (1) NZ606548A (lt)
PE (2) PE20130601A1 (lt)
PH (1) PH12013500235A1 (lt)
PL (2) PL2600830T3 (lt)
PT (2) PT3246016T (lt)
RS (2) RS66876B1 (lt)
SG (1) SG187258A1 (lt)
SI (2) SI2600830T1 (lt)
SM (1) SMT202500256T1 (lt)
TR (1) TR201807012T4 (lt)
UA (1) UA112296C2 (lt)
WO (1) WO2012016889A2 (lt)
ZA (1) ZA201300870B (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2012016845A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
CN103562185A (zh) 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
LT3293176T (lt) 2013-10-22 2021-03-25 Chiesi Farmaceutici S.P.A. Pde4 inhibitoriaus kristalinė forma
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
US20250058063A1 (en) 2021-12-21 2025-02-20 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CA3250500A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. CRYSTALLINE FORM OF A PHOSPHODIESTERASE 4 INHIBITOR
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
KR20250069950A (ko) 2022-09-22 2025-05-20 키에시 파르마슈티시 엣스. 피. 에이. 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기
KR20250069949A (ko) 2022-09-22 2025-05-20 키에시 파르마슈티시 엣스. 피. 에이. 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기
JP2025532672A (ja) 2022-09-22 2025-10-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホスホジエステラーゼ-4阻害剤の投与のためのカプセル吸入器

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
EP1015895B1 (de) 1997-09-16 2001-07-11 Trench Switzerland AG Spannungsteiler
WO2000053157A1 (en) 1999-03-05 2000-09-14 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP2266549B1 (en) 2000-06-27 2019-08-07 Vectura Limited Method of making particles for use in a pharmaceutical composition
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
ATE503517T2 (de) 2002-07-31 2011-04-15 Chiesi Farma Spa Pulverinhalator
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
MX2007014927A (es) * 2005-06-06 2008-02-15 Hoffmann La Roche Derivados de sulfonamida utiles como inhibidores de palmitoil transferasa de carnitina de higado.
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2012016845A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
CN103562185A (zh) 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
LT3293176T (lt) 2013-10-22 2021-03-25 Chiesi Farmaceutici S.P.A. Pde4 inhibitoriaus kristalinė forma

Also Published As

Publication number Publication date
ME03022B (me) 2018-10-20
US9132121B2 (en) 2015-09-15
EA201690541A1 (ru) 2016-07-29
CY1120605T1 (el) 2019-12-11
MX2013001172A (es) 2013-03-07
CA2807256A1 (en) 2012-02-09
ES2664175T3 (es) 2018-04-18
NO2600830T3 (lt) 2018-07-21
EP2600830A2 (en) 2013-06-12
HUE037620T2 (hu) 2018-09-28
PH12013500235A1 (en) 2016-05-25
MY179703A (en) 2020-11-11
SMT202500256T1 (it) 2025-09-12
EP3246016A1 (en) 2017-11-22
JP2013532705A (ja) 2013-08-19
EP3246016B1 (en) 2025-04-09
LT2600830T (lt) 2018-04-10
SG187258A1 (en) 2013-03-28
DK2600830T3 (en) 2018-03-12
PT3246016T (pt) 2025-06-25
US20150342936A1 (en) 2015-12-03
PT2600830T (pt) 2018-04-02
BR112013002506A2 (pt) 2016-05-31
CO6690744A2 (es) 2013-06-17
KR101805958B1 (ko) 2017-12-07
AR082443A1 (es) 2012-12-05
HUE071256T2 (hu) 2025-08-28
ES3033142T3 (en) 2025-07-31
HRP20180717T1 (hr) 2018-07-13
KR20130094784A (ko) 2013-08-26
DK3246016T3 (da) 2025-05-19
SI2600830T1 (en) 2018-05-31
EA027692B1 (ru) 2017-08-31
CN103052379A (zh) 2013-04-17
MX346424B (es) 2017-03-21
RS66876B1 (sr) 2025-07-31
WO2012016889A2 (en) 2012-02-09
EA024922B1 (ru) 2016-11-30
JP6004233B2 (ja) 2016-10-05
US9308200B2 (en) 2016-04-12
US20120031403A1 (en) 2012-02-09
PL3246016T3 (pl) 2025-06-16
SI3246016T1 (sl) 2025-06-30
FI3246016T3 (fi) 2025-07-08
CA2807256C (en) 2018-08-28
EA201390049A1 (ru) 2013-05-30
PL2600830T3 (pl) 2018-08-31
CL2013000293A1 (es) 2013-05-03
EP2600830B1 (en) 2018-02-21
WO2012016889A3 (en) 2012-04-19
NZ606548A (en) 2015-02-27
IL224517B (en) 2018-04-30
HRP20250711T1 (hr) 2025-08-15
AU2011287711A1 (en) 2013-02-21
RS57061B1 (sr) 2018-06-29
PE20130601A1 (es) 2013-05-30
PE20171256A1 (es) 2017-08-28
UA112296C2 (uk) 2016-08-25
CN106890165A (zh) 2017-06-27
TR201807012T4 (tr) 2018-06-21
MA34449B1 (fr) 2013-08-01
ZA201300870B (en) 2014-04-30
AU2011287711B2 (en) 2016-10-27
GEP20156343B (en) 2015-08-10

Similar Documents

Publication Publication Date Title
LT3246016T (lt) Sausų miltelių vaisto forma, apimanti fosfodiesterazės inhibitorių
FR25C1006I1 (fr) Inhibiteurs de pyrazolyl-quinoxaline kinase
EP2747815A4 (en) DRY POWDER INHALATION DEVICE
EP2558297A4 (en) Powder overlay
SMT201700008B (it) Composizione farmaceutica
BR112013014361A2 (pt) forma de dosagem
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
PT2696848T (pt) Nanossuspensões de fármaco liofilizadas
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
EP2890621A4 (en) Powder dispenser
DK3246018T3 (da) Farmaceutisk sammensætning
SMT201400143B (it) Inalatore di polvere secca
CR20130380A (es) Tableta dispensable en forma oral
DK2401917T3 (da) Belagte pulverartikler
IL232035A0 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
EE201300005A (et) Ravimkoostis
IT1402824B1 (it) Pacchetto di sigarette.
IL225785A0 (en) Heterocyclic compounds, compositions comprising the same and uses thereof
SG11201402400YA (en) Dry coated tablet
DK2628396T3 (da) Pulverblanding
BR112013010643A2 (pt) compostos heterocíclicos
BR112012031102A2 (pt) forma de dosagem oral sólida
BR112013008074A2 (pt) combinações farmacêuticas
IT1398244B1 (it) Pacchetto di sigarette.
DE112011101987T8 (de) Pulverbeschichtungsverfahren